Cargando…
Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults
BACKGROUND: Intradermal (ID) vaccination may alleviate COVID-19 vaccine shortages and vaccine hesitancy. METHODS: Persons aged ≥65 years who were vaccinated with 2-dose ChAdOx1 12–24 weeks earlier were randomized to receive a booster vaccination by either ID (20 µg mRNA-1273 or 10 µg BNT162b2) or in...
Autores principales: | Assantachai, Prasert, Niyomnaitham, Suvimol, Chatthanawaree, Wichai, Intalapaporn, Somboon, Muangpaisan, Weerasak, Phannarus, Harisd, Saichompoo, Rangsimatiti Binda, Sura-amonrattana, Unchana, Wongprompitak, Patimaporn, Toh, Zheng Quan, Licciardi, Paul V, Srisutthisamphan, Kanjana, Chokephaibulkit, Kulkanya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547455/ https://www.ncbi.nlm.nih.gov/pubmed/37141388 http://dx.doi.org/10.1093/infdis/jiad133 |
Ejemplares similares
-
Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations
por: Niyomnaitham, Suvimol, et al.
Publicado: (2023) -
Immunogenicity of a single dose of BNT162b2, ChAdOx1 nCoV-19, or CoronaVac against SARS-CoV-2 delta and omicron variants among previously infected adults: A randomized trial
por: Niyomnaitham, Suvimol, et al.
Publicado: (2022) -
Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
por: Niyomnaitham, Suvimol, et al.
Publicado: (2022) -
Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
por: Chayachinda, Chenchit, et al.
Publicado: (2023) -
Safety and immunogenicity of intradermal administration of fractional dose CoronaVac(®), ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
por: Chatsiricharoenkul, Somruedee, et al.
Publicado: (2022)